Heart Failure

 
HFpEF News: Dapagliflozin Improves Symptoms, Exercise Function in PRESERVED-HF
September 17, 2021

Dapagliflozin adds substantial improvements in symptoms, exercise function to demonstrated disease-modifying properties for patients with HFpEF.

ESC 2021: Empagliflozin Found Beneficial in Patients with Heart Failure Regardless of Ejection Fraction
August 27, 2021

In a pooled analysis of 2 key clinical trials, empagliflozin was beneficial in patients with heart failure with a reduced and preserved ejection fraction.

ESC 2021: EMPORER-Preserved: Empagliflozin Reduces Composite CV Endpoint in HFpEF
August 27, 2021

Empagliflozin in patients with HFpEF reduced by 21% the risk of cardiovascular death or heart failure hospitalization across all prespecified subgroups, including those with/without diabetes.